• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖与非肥胖患者的氟烷生物转化

Halothane biotransformation in obese and nonobese patients.

作者信息

Bentley J B, Vaughan R W, Gandolfi A J, Cork R C

出版信息

Anesthesiology. 1982 Aug;57(2):94-7. doi: 10.1097/00000542-198208000-00005.

DOI:10.1097/00000542-198208000-00005
PMID:7091749
Abstract

Serum levels of inorganic fluoride, trifluoroacetic acid, and bromide ion were measured at various time intervals following two hours of halothane anesthesia in 17 morbidly obese and eight nonobese patients. Ionic fluoride, a marker of reductive halothane metabolism, increased in the obese but not the nonobese patients. This is of concern since reductive halothane metabolism is associated with hepatoxicity in animals. In addition, serum bromide levels were higher after 48 h in the obese patients compared to the nonobese patients (mean +/- SE, 1,311 +/- 114 vs. 787 +/- 115 microM, P less than 0.01). Sedative levels of bromide were not attained in any patient. Peak trifluoroacetic acid levels were similar in the two patient groups. Sex age, medication intake, and smoking history had no influence on the halothane metabolite levels found in this study.

摘要

在17例病态肥胖患者和8例非肥胖患者中,于氟烷麻醉两小时后的不同时间间隔测量血清无机氟、三氟乙酸和溴离子水平。离子氟是氟烷还原代谢的标志物,在肥胖患者中升高,而在非肥胖患者中未升高。这令人担忧,因为氟烷还原代谢与动物肝毒性有关。此外,肥胖患者在48小时后的血清溴水平高于非肥胖患者(均值±标准误,1311±114对787±115微摩尔,P<0.01)。所有患者均未达到溴的镇静水平。两个患者组的三氟乙酸峰值水平相似。性别、年龄、药物摄入和吸烟史对本研究中发现的氟烷代谢物水平没有影响。

相似文献

1
Halothane biotransformation in obese and nonobese patients.肥胖与非肥胖患者的氟烷生物转化
Anesthesiology. 1982 Aug;57(2):94-7. doi: 10.1097/00000542-198208000-00005.
2
Anesthetic biotransformation and renal function in obese patients during and after methoxyflurane or halothane anesthesia.
Anesthesiology. 1975 Apr;42(4):451-7. doi: 10.1097/00000542-197504000-00015.
3
Metabolism of halothane in obese Fischer 344 rats.氟烷在肥胖型Fischer 344大鼠体内的代谢
Anesthesiology. 1989 Sep;71(3):431-7. doi: 10.1097/00000542-198909000-00020.
4
Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography.通过离子色谱法测定血浆和尿液中氟烷代谢物三氟乙酸和溴化物
J Chromatogr B Biomed Sci Appl. 1997 May 9;692(2):413-8. doi: 10.1016/s0378-4347(96)00527-0.
5
The effect of cimetidine on anesthetic metabolism and toxicity.西咪替丁对麻醉药物代谢及毒性的影响。
Anesth Analg. 1986 May;65(5):481-8.
6
Does evidence of reductive halothane biotransformation correlate with hepatic binding of metabolites in obese patients?
Anesth Analg. 1981 Aug;60(8):548-51.
7
Biotransformation of halothane in guinea pig liver slices.氟烷在豚鼠肝切片中的生物转化。
Drug Metab Dispos. 1990 Jul-Aug;18(4):514-8.
8
SGOT values following evidence of reductive biotransformation of halothane in man.氟烷在人体中发生还原生物转化后的谷草转氨酶值。
Anesthesiology. 1979 Aug;51(2):185-6. doi: 10.1097/00000542-197908000-00033.
9
Halothane and enflurane metabolite elimination during anaesthesia in man.
Eur J Anaesthesiol. 1987 May;4(3):175-82.
10
Serum bromide after general anaesthesia with halothane.氟烷全身麻醉后的血清溴化物
Acta Anaesthesiol Scand. 1979 Dec;23(6):513-18. doi: 10.1111/j.1399-6576.1979.tb01481.x.

引用本文的文献

1
Toxicity of inhaled agents after prolonged administration.长期给药后吸入性药物的毒性
J Clin Monit Comput. 2018 Aug;32(4):651-666. doi: 10.1007/s10877-017-0077-0. Epub 2017 Nov 2.
2
Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.非酒精性脂肪性肝病作为药物性肝毒性危险因素的作用。
J Clin Transl Res. 2017 Feb;3(Suppl 1):212-232. doi: 10.18053/jctres.03.2017S1.006. Epub 2017 Feb 12.
3
Effects of tail fat on recovery times of anesthesia with isoflurane in fat-tailed Iranian Lori-Bakhtiyari lambs.
尾脂对伊朗肥尾洛里-巴赫蒂亚里羔羊异氟烷麻醉恢复时间的影响。
Vet Res Forum. 2015 Summer;6(3):205-9. Epub 2015 Sep 15.
4
Impact of obesity on drug metabolism and elimination in adults and children.肥胖对成人和儿童药物代谢和消除的影响。
Clin Pharmacokinet. 2012 May 1;51(5):277-304. doi: 10.2165/11599410-000000000-00000.
5
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.系统方法在肥胖患者药代动力学自下而上评估中的应用:清除率的预期变化。
Clin Pharmacokinet. 2011 Dec 1;50(12):809-22. doi: 10.2165/11594420-000000000-00000.
6
Halothane hepatitis in Iran: a review of 59 cases.伊朗的氟烷性肝炎:59例病例回顾
World J Gastroenterol. 2008 Sep 14;14(34):5322-6. doi: 10.3748/wjg.14.5322.
7
Plasma fluoride concentration and urinary fluoride excretion in obese and non-obese patients following enflurane anesthesia.
J Anesth. 1987 Sep 1;1(2):148-54. doi: 10.1007/s0054070010148.
8
Comparative tolerability profiles of the inhaled anaesthetics.吸入麻醉剂的相对耐受性概况
Drug Saf. 1997 Mar;16(3):157-70. doi: 10.2165/00002018-199716030-00002.
9
Halothane and liver damage.氟烷与肝损伤。
Postgrad Med J. 1989 Mar;65(761):129-35. doi: 10.1136/pgmj.65.761.129.